CENTRO-01-0247-FEDER-011112
Obesity PreDiT – A phase II, multicenter, double-blind, controlled study to evaluate the influence of the biomarker GP0044 as an indicator of body weight and fat mass loss in males after treatment with GPP846.
Obesity PreDiT – A phase II, multicenter, double-blind, controlled study to evaluate the influence of the biomarker GP0044 as an indicator of body weight and fat mass loss in males after treatment with GPP846.